


FACT SHEET: SENHANCE™ SURGICAL SYSTEM HIGHLIGHTS


- ✓ The Senhance Surgical System is 510(k) cleared by the FDA for use in laparoscopic gynecological surgery, colorectal surgery, cholecystectomy, and inguinal hernia repair. **Over 6 million applicable procedures are performed annually in the United States and the EU.** Senhance is CE marked according to the MDD and is intended to be used for laparoscopic surgery in the abdomen and pelvis of adults.
- ✓ The Senhance has been developed to aid in the transition to a new era of digital laparoscopy to help drive value-based healthcare, bringing the benefits of robotics to high volume, multi-specialty surgeries. We aspire to improve predictability and ergonomics in the OR to optimize the surgical experience for surgeons and patients.
- ✓ The Senhance is designed to enhance the precision, senses and control of surgeons in performing minimally invasive laparoscopic procedures. The system builds on the foundations of laparoscopy and features the security of haptic feedback and eye-sensing camera control for the first time in a robotic surgery platform—making the transition to robotically-assisted laparoscopic procedures easier for laparoscopic surgeons, allowing for accelerated adoption, and supporting a rapid utilization ramp.
- ✓ Additionally, the company's open platform strategy enables hospitals and surgeons to leverage existing technology investments within the existing operating room ecosystem, and the company continues to expand the list of technologies enabled by this strategy.
- ✓ The system is specifically engineered to manage operative time and costs effectively, making robotic surgery cost-effective on a per-procedure basis through the use of fully reusable instruments, which will allow surgeons and hospitals the opportunity to bring the benefits of robotics to a significantly broader patient population than current robotics.



SENHANCE SURGICAL SYSTEM IN THE U.S.

SENHANCE™ SURGICAL SYSTEM OPPORTUNITY

Hospitals and surgeons face intense pressure to reduce costs, increase efficiencies, and improve the quality of patient care. A significantly expanded number of surgeons, and in turn patients, may benefit from the first digital laparoscopy platform that delivers the familiarity of laparoscopic surgery with the addition of haptics, eye-tracking camera control, arm stabilization, seated console and 3D imaging.



SENHANCE SURGICAL SYSTEM IN THE E.U.

DIGITAL LAPAROSCOPY WITH THE SENHANCE™ SYSTEM:

- **The Benefits of Laparoscopy:** The system is designed for a minimal learning curve with familiar laparoscopic motion, trocars and approach to help quickly achieve efficient and effective clinical operations.
- **Advanced Control & Digitized Laparoscopy:** Allows surgeon simultaneous control of multiple robotic arms, instruments and a camera with precision and dexterity; instrument clutching promotes surgeon ergonomics.

AT A GLANCE:

- Stock Symbol: TRXC
- Stock Exchange: NYSE American

ANALYST COVERAGE:

- Stifel: Rick Wise
- RBC Capital Markets: Glenn Novarro
- Raymond James: Lawrence Keusch
- Ladenburg Thalmann & Co. Inc.: Jeffrey Cohen
- BTIG LLC: Sean Lavin, MD

- **Open Platform Strategy:** Senhance is able to work with, instead of competing against, some of the biggest players in laparoscopic devices, which is a benefit to hospitals, surgeons, and patients, facilitating access to vital surgeon-preference items and evolving technology.
- **Eye-Tracking Capabilities:** Allows surgeon to seamlessly control vision during a robotic surgery procedure, operating without stopping to reposition the camera.
- **Haptic Feedback:** Allows surgeon to operate with sense of force feedback to provide vital information on forces applied during delicate surgery.
- **Reduce Fatigue and Strain on Surgeon:** The platform console allows for the surgeon to be seated in an ergonomically comfortable position throughout the procedure. The robotic system stabilizes instruments and allows for the surgeon to easily reposition their hands during surgery to avoid any awkward positions while performing delicate tasks.
- **OR Efficiency:** Designed for quick system and instrument setup and OR turnover; designed to minimize reliance on OR staff.

COMPANY OVERVIEW

TransEnterix is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today's value-based healthcare environment. The Company is focused on the commercialization of the Senhance Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics.

FORWARD-LOOKING STATEMENT: The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. The forward-looking statements contained in this document are subject to certain risks and uncertainties. Actual results could differ materially from current expectations. The information contained herein is not a prospectus and does not constitute an offer to sell nor a solicitation of an offer to buy any security.

www.transenterix.com | Main phone: 888-879-4111 | 635 Davis Drive, Suite 300, Morrisville, NC 27560

© 2018 TransEnterix Surgical, Inc. All rights reserved. Senhance is a trademark of TransEnterix Surgical, Inc.

In the US: The Senhance™ Surgical System is intended to be used in laparoscopic gynecological surgery, colorectal surgery, cholecystectomy, and inguinal hernia repair. The system is indicated for adult use.

In the EU: The Senhance™ Surgical System is CE marked according to the MDD and is intended to be used for laparoscopic surgery in the abdomen and pelvis of adults. The device is restricted to sale by or on the order of a physician. RADIA articulating instrumentation is only currently available in CE Markets. Four manipulator arm configuration is only currently available in CE Markets. Senhance was developed under a license of the European Commission Joint Research Centre.